287 related articles for article (PubMed ID: 29103883)
1. Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.
Walker MS; Wong W; Ravelo A; Miller PJE; Schwartzberg LS
Clin Lung Cancer; 2018 Mar; 19(2):139-147. PubMed ID: 29103883
[TBL] [Abstract][Full Text] [Related]
2. Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
Sztankay M; Giesinger JM; Zabernigg A; Krempler E; Pall G; Hilbe W; Burghuber O; Hochmair M; Rumpold G; Doering S; Holzner B
BMC Cancer; 2017 Aug; 17(1):565. PubMed ID: 28835219
[TBL] [Abstract][Full Text] [Related]
3. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
von Verschuer U; Schnell R; Tessen HW; Eggert J; Binninger A; Spring L; Jänicke M; Marschner N;
Lung Cancer; 2017 Oct; 112():216-224. PubMed ID: 28916198
[TBL] [Abstract][Full Text] [Related]
4. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
7. Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data.
Shallwani SM; Simmonds MJ; Kasymjanova G; Spahija J
Lung Cancer; 2016 Sep; 99():69-75. PubMed ID: 27565917
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.
Lagerwaard FJ; Aaronson NK; Gundy CM; Haasbeek CJ; Slotman BJ; Senan S
J Thorac Oncol; 2012 Jul; 7(7):1148-54. PubMed ID: 22610256
[TBL] [Abstract][Full Text] [Related]
9. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA; Belderbos JSA; Reymen B; Lambrecht M; Fredberg Persson G; Faivre-Finn C; Dieleman EMT; van Diessen JNA; Sonke JJ; de Ruysscher D
Radiother Oncol; 2024 Jul; 196():110312. PubMed ID: 38663582
[TBL] [Abstract][Full Text] [Related]
11. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
Basch E; Schrag D; Henson S; Jansen J; Ginos B; Stover AM; Carr P; Spears PA; Jonsson M; Deal AM; Bennett AV; Thanarajasingam G; Rogak LJ; Reeve BB; Snyder C; Bruner D; Cella D; Kottschade LA; Perlmutter J; Geoghegan C; Samuel-Ryals CA; Given B; Mazza GL; Miller R; Strasser JF; Zylla DM; Weiss A; Blinder VS; Dueck AC
JAMA; 2022 Jun; 327(24):2413-2422. PubMed ID: 35661856
[TBL] [Abstract][Full Text] [Related]
12. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
[TBL] [Abstract][Full Text] [Related]
13. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S; Shaw AT; Besse B; Felip E; Solomon BJ; Soo RA; Bearz A; Gadgeel SM; Lin CC; Kao S; Seto T; Masters ET; Abbattista A; Clancy JS; Thurm H; Reisman A; Peltz G; Ross Camidge D
Lung Cancer; 2020 Jun; 144():10-19. PubMed ID: 32344248
[TBL] [Abstract][Full Text] [Related]
14. The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.
de Mol M; Visser S; Aerts J; Lodder P; van Walree N; Belderbos H; den Oudsten B
BMC Cancer; 2020 May; 20(1):431. PubMed ID: 32423432
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer.
Ran J; Wang J; Bi N; Jiang W; Zhou Z; Hui Z; Liang J; Feng Q; Wang L
Radiat Oncol; 2017 Dec; 12(1):195. PubMed ID: 29197373
[TBL] [Abstract][Full Text] [Related]
16. Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials.
Hallqvist A; Bergman B; Nyman J
Radiother Oncol; 2012 Jul; 104(1):39-44. PubMed ID: 22727262
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Bordoni R; Ciardiello F; von Pawel J; Cortinovis D; Karagiannis T; Ballinger M; Sandler A; Yu W; He P; Matheny C; Felizzi F; Rittmeyer A
Clin Lung Cancer; 2018 Sep; 19(5):441-449.e4. PubMed ID: 30017645
[TBL] [Abstract][Full Text] [Related]
18. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.
Katakami N; Kunikane H; Takeda K; Takayama K; Sawa T; Saito H; Harada M; Yokota S; Ando K; Saito Y; Yokota I; Ohashi Y; Eguchi K
J Thorac Oncol; 2014 Feb; 9(2):231-8. PubMed ID: 24419421
[TBL] [Abstract][Full Text] [Related]
19. EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC).
Pompili C; Koller M; Velikova G; Franks K; Absolom K; Callister M; Robson J; Imperatori A; Brunelli A
Lung Cancer; 2018 Sep; 123():149-154. PubMed ID: 30089587
[TBL] [Abstract][Full Text] [Related]
20. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Hirsh V; Cadranel J; Cong XJ; Fairclough D; Finnern HW; Lorence RM; Miller VA; Palmer M; Yang JC
J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]